Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
An Economist’s Change of Heart: It’s Time to Regulate the Prescription- Drug Middlemen
Pharmacy-benefit managers find ways to boost their bottom line at the expense of employers and patients, writes Geoffrey Joyce in Market Watch.
-
Medicare’s ‘Catastrophic Insurance’ Can Be a Catastrophe for Middle-Income Seniors
Even with Medicare's catastrophic insurance, middle-income seniors can be on the hook for thousands of dollars for their medications each year, write Erin Trish and Geoffrey Joyce in STAT.
Posted in -
Who Wins When a Prescription Copay Exceeds the Drug Price? (Not the Patient)
An interactive graphic shows how frequently the co-payment exceeds the price of commonly prescribed drugs, and provides the average overpayment per drug.
Posted in -
Cultivating a Vibrant U.S. Market for Biosimilars: a Conversation with FDA’s Scott Gottlieb
Biosimilars have been a major focus of the FDA’s efforts to increase competition and choice for patients and the U.S. healthcare system.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Productivity Benefits of Medical Care: Evidence from US-Based Randomized Clinical Trials
Drug innovation in the last decade increased productivity by 4.8 million work days, resulting in $221 billion in annual wages.
Categorized in -
Economics of the Pharmaceutical Industry
Darius Lakdawalla reviews the economics literature on the pharmaceutical industry, focusing particularly on its positive and normative implications for the innovation, pricing, and marketing decisions of pharmaceutical firms.
Categorized in -
New Payment Strategy Could Help States Treat More Hepatitis C Patients While Encouraging Innovation
A curative treatment exists for chronic hepatitis C infection, yet many Medicaid beneficiaries do not have access to these drugs. Neeraj Sood and his colleagues have developed a novel pricing strategy to expand access.
-
Why Health Price Regulations in California are Misguided
Imposing uniform payment rates is dangerous and misguided, writes Trish and Goldman in the Sacramento Bee.
Categorized in -
USC Recruits Diverse Participants for Landmark $1.5 Billion Precision Medicine Research Initiative
Nationwide big data project seeks to accelerate research and improve health for a diverse population, not just majority groups.
-
Accelerating Alzheimer’s Disease Drug Innovations from the Research Pipeline to Patients
Goldman, Fillit, and Neumann outline policy options that would lead to more innovation.
Categorized in